Arzerra

Active Ingredient(s): Ofatumumab
FDA Approved: * October 26, 2009
Pharm Company: * GLAXO GRP LTD
Category: Cancer

Ofatumumab is a fully human monoclonal antibody to CD20, which appears to inhibit early-stage B lymphocyte activation. Under the brand name Arzerra, it is approved for the treatment of certain types of chronic lymphocytic leukemia (CLL) in the United States.[6] Under the brand name Kesimpta, it is approved for the treatment of multiple sclerosis in the United States as well as in the EU and other regions.[7][9] The most common side effects for o... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Arzerra 20 mg/ml Intravenous Injection, Solution
NDC: 0078-0669
Labeler:
Novartis Pharmaceuticals Corporation
Arzerra 20 mg/ml Intravenous Injection, Solution
NDC: 0078-0690
Labeler:
Novartis Pharmaceuticals Corporation
Arzerra 20 mg/ml Intravenous Injection, Solution
NDC: 0173-0821
Labeler:
Glaxosmithkline LLC
Arzerra 20 mg/ml Intravenous Injection, Solution
NDC: 63379-023
Labeler:
Glaxo Operations Uk Ltd